Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -73.31% | 42.68% | 75.69% | 113.80% | 145.38% |
| Gross Profit | 73.31% | -42.68% | -75.69% | -113.80% | -145.38% |
| SG&A Expenses | 24.37% | 33.91% | 87.85% | 111.50% | 129.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.02% | 40.83% | 78.09% | 113.32% | 141.90% |
| Operating Income | -20.02% | -40.83% | -78.09% | -113.32% | -141.90% |
| Income Before Tax | -26.54% | -45.49% | -77.80% | -100.39% | -123.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.54% | -45.49% | -77.80% | -100.39% | -123.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.54% | -45.49% | -77.80% | -100.39% | -123.57% |
| EBIT | -20.02% | -40.83% | -78.09% | -113.32% | -141.90% |
| EBITDA | -37.66% | -16.37% | -75.21% | -130.89% | -158.61% |
| EPS Basic | -5.71% | 86.96% | 92.44% | 95.06% | 95.63% |
| Normalized Basic EPS | -7.15% | 86.94% | 92.43% | 95.05% | 95.69% |
| EPS Diluted | -5.71% | 86.96% | 92.44% | 95.06% | 95.63% |
| Normalized Diluted EPS | -7.15% | 86.94% | 92.43% | 95.05% | 95.69% |
| Average Basic Shares Outstanding | 15.49% | 56.17% | 153.03% | 570.06% | 5,103.62% |
| Average Diluted Shares Outstanding | 15.49% | 56.17% | 153.03% | 570.06% | 5,103.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |